Healthcare

Pharmacovigilance Market Size to Touch US$ 18.36 billion by 2030

The global pharmacovigilance market size was valued at USD 5.97 billion in 2020, and is predicted to be worth around USD 18.36 billion by 2030, registering a CAGR of 10.6% during the forecast period 2022 to 2030.

Pharmacovigilance Market (By Service Provider: In-house, Contract Outsourcing; By Product Life Cycle: Pre-clinical, Phase I, Phase II, Phase III, Phase IV; By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining; By Process Flow: Case Data Management, Signal Detection, Risk Management System) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030

Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/39099

Growth Factors

Increasing incidence of Adverse Drug Reactions (ADRs) is the key growth driver. ADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.

An increase in the prevalence of chronic diseases such as oncological diseases, diabetes, and cardiovascular and respiratory disorders has led to an increase in drug consumption worldwide. Therefore, the demand for new drug development via extensive clinical trials has increased. Pharmacovigilance (PV) is the inevitable part of drug discovery and development procedures.

Key Players

  • Accenture
  • Linical Accelovance
  • Cognizant
  • Laboratory Corporation of America Holdings
  • IBM Corporation
  • ArisGlobal
  • ICON plc.
  • Capgemini
  • ITClinical
  • FMD K&L
  • IQVIA
  • TAKE Solutions Ltd.
  • PAREXEL International Corporation
  • BioClinica Inc.
  • Wipro Ltd.
  • United BioSource Corporation

Market Segmentation

  • By Service Provider
    • In-house
    • Contract Outsourcing
  • By Product Life Cycle
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • By Type
    • Spontaneous Reporting
    • Intensified ADR Reporting
    • Targeted Spontaneous Reporting
    • Cohort Event Monitoring
    • EHR Mining
  • By Process Flow
    • Case Data Management
      • Case Logging
      • Case Data Analysis
      • Medical Reviewing & Reporting
    • Signal Detection
      • Adverse Event Logging
      • Adverse Event Analysis
      • Adverse Event Review & Reporting
    • Risk Management System
      • Risk Evaluation System
      • Risk Mitigation System
  • By Therapeutic Area
    • Oncology
    • Neurology
    • Cardiology
    • Respiratory Systems
    • Others
  • By End-use
    • Pharmaceuticals
    • Biotechnology Companies
    • Medical Device Manufacturers
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Russia
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East and Africa
      • South Africa
      • Kingdom of Saudi Arabia

Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/39099

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2019-2021) and forecast (2022-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Pharmacovigilance Market, By Service Provider

7.1.  Pharmacovigilance Market, by Service Provider, 2021-2030

7.1.1.    In-house

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Contract Outsourcing

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Pharmacovigilance Market, By Product Life Cycle

8.1.  Pharmacovigilance Market, by Product Life Cycle, 2021-2030

8.1.1.    Pre-clinical

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Phase I

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Phase II

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Phase III

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Phase IV

8.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Pharmacovigilance Market, By Type

9.1.  Pharmacovigilance Market, by Type, 2021-2030

9.1.1.    Spontaneous Reporting

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Intensified ADR Reporting

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Targeted Spontaneous Reporting

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Cohort Event Monitoring

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    EHR Mining

9.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Pharmacovigilance Market, By Process Flow

10.1.        Pharmacovigilance Market, by Process Flow, 2021-2030

10.1.1.  Case Data Management

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Signal Detection

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Risk Management System

10.1.3.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Pharmacovigilance Market, By Therapeutic Area

11.1.        Pharmacovigilance Market, by Therapeutic Area, 2021-2030

11.1.1.  Oncology

11.1.1.1.      Market Revenue and Forecast (2017-2030)

11.1.2.  Neurology

11.1.2.1.      Market Revenue and Forecast (2017-2030)

11.1.3.  Cardiology

11.1.3.1.      Market Revenue and Forecast (2017-2030)

11.1.4.  Respiratory Systems

11.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 12.      Global Pharmacovigilance Market, By End-use

12.1.        Pharmacovigilance Market, by End-use, 2021-2030

12.1.1.  Pharmaceuticals

12.1.1.1.      Market Revenue and Forecast (2017-2030)

12.1.2.  Biotechnology Companies

12.1.2.1.      Market Revenue and Forecast (2017-2030)

12.1.3.  Medical Device Manufacturers

12.1.3.1.      Market Revenue and Forecast (2017-2030)

12.1.4.  Others

12.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 13.      Global Pharmacovigilance  Market, Regional Estimates and Trend Forecast

13.1.        North America

13.1.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.1.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.1.3.  Market Revenue and Forecast, by Type (2017-2030)

13.1.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.1.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.1.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.1.7.  U.S.

13.1.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.1.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.1.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.1.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.1.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.1.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.1.8.  Rest of North America

13.1.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.1.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.1.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.1.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.1.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.1.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.        Europe

13.2.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.3.  Market Revenue and Forecast, by Type (2017-2030)

13.2.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.2.7.  UK

13.2.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.2.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.8.  Germany

13.2.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.2.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.9.  France

13.2.9.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.9.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.9.3.      Market Revenue and Forecast, by Type (2017-2030)

13.2.9.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.9.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.9.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.10.               Rest of Europe

13.2.10.1.   Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.10.2.   Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.10.3.   Market Revenue and Forecast, by Type (2017-2030)

13.2.10.4.   Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.10.5.   Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.10.6.   Market Revenue and Forecast, by End-use (2017-2030)

13.3.        APAC

13.3.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.3.  Market Revenue and Forecast, by Type (2017-2030)

13.3.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.3.7.  India

13.3.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.3.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.3.8.  China

13.3.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.3.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.3.9.  Japan

13.3.9.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.9.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.9.3.      Market Revenue and Forecast, by Type (2017-2030)

13.3.9.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.9.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.9.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.3.10.               Rest of APAC

13.3.10.1.   Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.10.2.   Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.10.3.   Market Revenue and Forecast, by Type (2017-2030)

13.3.10.4.   Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.10.5.   Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.10.6.   Market Revenue and Forecast, by End-use (2017-2030)

13.4.        MEA

13.4.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.3.  Market Revenue and Forecast, by Type (2017-2030)

13.4.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.4.7.  GCC

13.4.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.4.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.4.8.  North Africa

13.4.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.4.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.4.9.  South Africa

13.4.9.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.9.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.9.3.      Market Revenue and Forecast, by Type (2017-2030)

13.4.9.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.9.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.9.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.4.10.               Rest of MEA

13.4.10.1.   Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.10.2.   Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.10.3.   Market Revenue and Forecast, by Type (2017-2030)

13.4.10.4.   Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.10.5.   Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.10.6.   Market Revenue and Forecast, by End-use (2017-2030)

13.5.        Latin America

13.5.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.5.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.5.3.  Market Revenue and Forecast, by Type (2017-2030)

13.5.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.5.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.5.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.5.7.  Brazil

13.5.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.5.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.5.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.5.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.5.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.5.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.5.8.  Rest of LATAM

13.5.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.5.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.5.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.5.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.5.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.5.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

Chapter 14.  Company Profiles

14.1.              Accenture

14.1.1.  Company Overview

14.1.2.  Product Offerings

14.1.3.  Financial Performance

14.1.4.  Recent Initiatives

14.2.              Linical Accelovance

14.2.1.  Company Overview

14.2.2.  Product Offerings

14.2.3.  Financial Performance

14.2.4.  Recent Initiatives

14.3.              Cognizant

14.3.1.  Company Overview

14.3.2.  Product Offerings

14.3.3.  Financial Performance

14.3.4.  Recent Initiatives

14.4.              Laboratory Corporation of America Holdings

14.4.1.  Company Overview

14.4.2.  Product Offerings

14.4.3.  Financial Performance

14.4.4.  Recent Initiatives

14.5.              IBM Corporation

14.5.1.  Company Overview

14.5.2.  Product Offerings

14.5.3.  Financial Performance

14.5.4.  Recent Initiatives

14.6.              ArisGlobal

14.6.1.  Company Overview

14.6.2.  Product Offerings

14.6.3.  Financial Performance

14.6.4.  Recent Initiatives

14.7.              ICON plc.

14.7.1.  Company Overview

14.7.2.  Product Offerings

14.7.3.  Financial Performance

14.7.4.  Recent Initiatives

14.8.              Capgemini

14.8.1.  Company Overview

14.8.2.  Product Offerings

14.8.3.  Financial Performance

14.8.4.  Recent Initiatives

14.9.              ITClinical

14.9.1.  Company Overview

14.9.2.  Product Offerings

14.9.3.  Financial Performance

14.9.4.  Recent Initiatives

14.10.           FMD K&L

14.10.1.               Company Overview

14.10.2.               Product Offerings

14.10.3.               Financial Performance

14.10.4.               Recent Initiatives

Chapter 15.  Research Methodology

15.1.              Primary Research

15.2.              Secondary Research

15.3.              Assumptions

Chapter 16.  Appendix

16.1.              About Us

Glossary of Terms

Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/39099

About Us: Our team of skilled and experienced analysts specializes in troubleshooting problems faced by our clients. For comprehensive summary of our services and market research requirements for Global industry.

Contact Us:

call: +1 9197 992 333

Vision Research Report

Any Assistance, Email – sales@visionresearchreports.com

Show More

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button